VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES

VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES

The effectiveness of traditional chemotherapy (with temozolomide, fotemustine, lomustine) alone or in combination with whole brain radiotherapy in melanoma patients with cerebral metastases does not exceed 7–10 % with no significant impact on survival, which is around 2–4 months. Targeted therapy...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. R. Naskhletashvili, V. A. Gorbunova, A. Kh. Bekyashev, L. V. Demidov, G. Yu. Kharkevich, S. M. Banov, I. V. Samoylenko, K. А. Baryshnikov, K. V. Orlova, I. А. Utyashev, N. N. Petenko, I. G. Markina, E. A. Moskvina, S. V. Medvedev
Format:	Article
Language:	Russian
Published:	ABV-press 2017-04-01
Series:	Опухоли головы и шеи
Subjects:	vemurafenib melanoma brain metastases targeted therapy
Online Access:	https://ogsh.abvpress.ru/jour/article/view/248
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Vemurafenib resistant melanoma cells acquire mesenchymal stem cell-like properties
by: A. A. Vartanian, et al.
Published: (2019-12-01)

Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case
by: V. E. Askarov, et al.
Published: (2025-07-01)

Into the Groove: A Multitechnique Insight into the DNA–Vemurafenib Interaction
by: Gabriele Cavalieri, et al.
Published: (2024-10-01)

Novel transferosome formulation of Vemurafenib for skin cancer management: biocompatible and scalable strategies
by: Tariq M. Aljarba, et al.
Published: (2025-08-01)

Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials
by: Taylor Gardner, et al.
Published: (2025-05-01)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022-07-01)

INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
by: Mouna Jameleddine, et al.
Published: (2024-10-01)

Vemurafenib Induces Senescent Phenotype with Increased Adhesion in BRAF Mutant A375 but not in Wild Type BRAF SK-MEL-2 Melanoma Cells
by: Aleksandra Rashidovna Esimbekova, et al.
Published: (2025-04-01)

Continuous ultraviolet irradiation induces the development of irreversible resistance of melanoma cells to anticancer drugs
by: Yu. Yu. Shchegolev, et al.
Published: (2023-10-01)

Langerhans cell histiocytosis in adults: literature review
by: V. G. Potapenko, et al.
Published: (2022-11-01)

MelCher5k/<i>BRAF</i><sup>+</sup> subcutaneous human melanoma xenograft with CD20 expression
by: I. N. Mikhaylova, et al.
Published: (2025-06-01)

COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
by: Ada Ndoja, et al.
Published: (2025-06-01)

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation
by: Yilamujiang Ainiwan, et al.
Published: (2025-03-01)

CAPECITABINE IN THE TREATMENT OF BRAIN METASTATIC LESION IN PATIENTS WITH BREAST CANCER
by: E. A. Moskvina, et al.
Published: (2015-04-01)

Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma
by: Wenhao Shi, et al.
Published: (2025-07-01)

Difficulties associated with differential diagnosis between brain metastases and foci of necrosis resulted from stereotactic radiotherapy (case report and literature review)
by: А. V. Nazarenko, et al.
Published: (2019-10-01)

ROLE OF TARGETED THERAPY IN THE COMBINATION TREATMENT OF PATIENTS WITH KIDNEY CANCER AND METASTATIC BRAIN INVOLVEMENT
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

GEFITINIB (IRESSA) IN THE TREATMENT OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CARCINOMA
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

СRANIAL AND INTRACRANIAL METASTASES OF THYROID CANCER
by: V. B. Karakhan, et al.
Published: (2015-04-01)

CHEMO- AND TARGET THERAPY OF PATIENTS WITH BREAST CANCER WITH METASTATIC BRAIN LESIONS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Molecular and genetic diversity in melanoma of eye
by: N. N. Mazurenko, et al.
Published: (2018-11-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

RESULTS OF RADIOSURGICAL AND DRUG TREATMENT OF PATIENTS WITH BRAIN METASTASES
by: S. M. Banov, et al.
Published: (2017-11-01)

A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases
by: Idit Melnik, et al.
Published: (2013-01-01)

Combination chemotherapy in the treatment of breast cancer patients with metastatic brain involvement and a poor prognosis
by: D. R. Naskhletashvili, et al.
Published: (2014-07-01)

Prognostic factors for overall survival and intracranial progression in patients with renal cancer metastasis into the brain after neurosurgical treatment
by: K. E. Roshchina, et al.
Published: (2022-12-01)

Modern strategies for the treatment of patients with kidney cancer of brain metastases: literature review
by: K. E. Roshchina, et al.
Published: (2022-04-01)

SURGICAL TREATMENT OF HEAD AND NECK CUTANEOUS MELANOMA: A MODERN APPROACH TO THE PROBLEM
by: M. B. Pak, et al.
Published: (2017-04-01)

SURGICAL TACTICS REGARDING CEREBRAL METASTASES WITH HEMORRHAGES
by: E. V. Prozorenko, et al.
Published: (2015-04-01)

МЕТОДИЧНІ ОСНОВИ ПЛАНУВАННЯ Й УПРАВЛІННЯ ВИТРАТАМИ ПРИ ПІДГОТОВЦІ ДО ЕКСПЛУАТАЦІЇ Й ВІДПРАЦЮВАННІ НОВИХ ВИЇМКОВИХ ПОЛІВ
by: I.V. Petenko, et al.
Published: (2024-10-01)

A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia
by: QIU Yuchong, et al.
Published: (2025-01-01)

Transarterial chemoembolization for patients with metastatic uveal melanoma in the liver
by: B. I. Dolgushin, et al.
Published: (2016-09-01)

CEREBRAL METASTASES CANCER OF THE LARYNX: TWO CASE REPORTS
by: N. V. Sevyan, et al.
Published: (2015-04-01)

Fundamental Provisions of the Concept of Balanced Interaction of Society and Nature as Basis of Sustainable Development of the World
by: A. V. Demidov, et al.
Published: (2022-06-01)

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
by: Monika Joshi, et al.
Published: (2015-01-01)

Inter-Relationship Between Melanoma Vemurafenib Tolerance Thresholds and Metabolic Pathway Choice
by: Pratima Nangia-Makker, et al.
Published: (2025-06-01)

Brain metastases from esophageal cancer: a case-report
by: N. V. Sevian, et al.
Published: (2020-07-01)

Renal carcinoma with brain metastases. Prognostic factors and treatment outcomes
by: A. V. Golanov, et al.
Published: (2016-10-01)

SIGNIFICANCE OF SINGLE-NUCLEOTIDE POLYMORPHISMS 2578C>A AND +936C>T IN THE VEGF GENE FOR EFFICIENCY EVALUAT ION OF ANTICANCER IMMUNOTHERAPY IN PAT IENTS WITH METASTAT IC SKIN MELANOMA
by: Yu. A. Khochenkova, et al.
Published: (2014-07-01)

Does morphology have real impact on local and distant recurrences in head and neck cutaneous melanoma?
by: A. M. Mudunov, et al.
Published: (2020-11-01)